Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - May 2013


Translational CNS Summit

21 May 2013 - 23 May 2013 - Boston, MA, USA



Bookmark and Share


Increase the translational potential of your CNS therapies

Bridge the Translational Gap

CNS diseases are a huge unmet medical need in our society. Why? Because CNS drug discovery is notoriously difficult. But for the companies that get it right and produce new successful therapeutics, the rewards, both commercially and socially will be huge. So what can be done to ensure more CNS drugs make it to market?

The problems drug developers face tend to be very similar across the industry. Unreliable animal models. Validating new biomarkers. Detecting if a drug has reached the brain. However the solutions to tackle these problems are different across the board. There is a real hunger for a consolidation of ideas to decide what is best practice.


Translational CNS is first and foremost a summit, a meeting of leading minds in the CNS field. Where the key issues can be discussed, where progress can be made, where people can decide how to mitigate risk of failure.

The agenda has been designed by experts from Eli Lilly, Takeda, Eisai and more. It will cover how to avoid the pitfalls that cause CNS drugs to fail and enable you to increase the clinical success rate of your CNS drugs

Key topics covered include:

Designing animal models with improved predictive validity

Optimizing the use of imaging within your clinical development

Identifying and validating new biomarkers of CNS disease

Bridging the gap between preclinical and clinical developmente the translational potential of your CNS therapies

Bridge the Translational Gap

CNS diseases are a huge unmet medical need in our society. Why? Because CNS drug discovery is notoriously difficult. But for the companies that get it right and produce new successful therapeutics, the rewards, both commercially and socially will be huge. So what can be done to ensure more CNS drugs make it to market?

The problems drug developers face tend to be very similar across the industry. Unreliable animal models. Validating new biomarkers. Detecting if a drug has reached the brain. However the solutions to tackle these problems are different across the board. There is a real hunger for a consolidation of ideas to decide what is best practice.

Translational CNS is first and foremost a summit, a meeting of leading minds in the CNS field. Where the key issues can be discussed, where progress can be made, where people can decide how to mitigate risk of failure.

The agenda has been designed by experts from Eli Lilly, Takeda, Eisai and more. It will cover how to avoid the pitfalls that cause CNS drugs to fail and enable you to increase the clinical success rate of your CNS drugs

Key topics covered include:

Designing animal models with improved predictive validity

Optimizing the use of imaging within your clinical development

Identifying and validating new biomarkers of CNS disease

Bridging the gap between preclinical and clinical development



Further information
Scientific News
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
Making Injectable Medicine Safer
Researchers remove excess additives from drugs, which could reduce the odds of serious allergic reactions and other side effects.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!